SAB Biotherapeutics (SABS) EPS (Basic) (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly EPS (Basic) came in at -$0.35 in Q1 2026, up 37.01% YoY from -$0.26 in Q1 2025, and down 4.29% on a QoQ basis from -$0.34 in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) EPS (Basic) (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of EPS (Basic) data on file, last reported at -$0.35 in Q1 2026.
- Quarterly EPS (Basic) rose 37.01% year-over-year to -$0.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.06 (up 71.22% YoY) and the FY2025 annual result came in at -$1.64, up 55.38% from the prior year.
- EPS (Basic) retreated to -$0.35 in Q1 2026, from -$0.34 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $0.23 in Q1 2022 to a low of -$4.14 in Q4 2023.
- A 5-year average of -$1.15 and a median of -$1.11 in 2022 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) jumped 83.22% — and 2023, when it plunged 738.12%.
- Tracing SABS's EPS (Basic) over 5 years: stood at -$1.81 in 2022, then sank by 128.81% to -$4.14 in 2023, then soared by 70.28% to -$1.23 in 2024, then soared by 72.54% to -$0.34 in 2025, then slipped by 4.29% to -$0.35 in 2026.
- The last three EPS (Basic) figures came in at -$0.35 (Q1 2026), -$0.34 (Q4 2025), and -$1.2 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | SAB Biotherapeutics | 295.88 Mn | 295.88 Mn | - | -0.28 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.28 |
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | -0.78 |
| Sep 30, 2025 | -1.13 |
| Jun 30, 2025 | -1.09 |
| Mar 31, 2025 | -0.56 |
| Dec 31, 2024 | -1.23 |
| Sep 30, 2024 | -1.12 |
| Jun 30, 2024 | -0.79 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -4.14 |
| Sep 30, 2023 | -0.97 |
| Jun 30, 2023 | -1.36 |
| Mar 31, 2023 | -1.46 |
| Dec 31, 2022 | -1.81 |
| Sep 30, 2022 | -1.64 |
| Jun 30, 2022 | -1.11 |
| Mar 31, 2022 | 0.23 |
| Dec 31, 2021 | -4.23 |
| Sep 30, 2021 | -2.75 |